About MedX
MedX Health Corporation
Mission Statement: To develop and commercialize non-invasive, drug-free and cost-effective laser and light therapeutics and imaging systems that enhance the patient’s quality of life and improve their standard of care.
History & Overview
MedX Health Corporation was incorporated in 1999, and began selling laser and light devices in Canada from its facility in Ontario, Canada. The Founder and CEO was Phil Passy. In 2002, the MedX products received FDA approval and sales began in the US. The primary markets for these products were in sports, rehab, and chiropractic medicine, to reduce pain and swelling and accelerate healing. Between 2002 and 2008 MedX Health entered several new markets, including dental and acupuncture medicine, and began research on a product line designed to treat and monitor wounds, such as bed sores and diabetic foot ulcers.
The MedX Founder and CEO, Phil Passy passed away unexpectedly in February of 2008, following the completion of an IPO, just 10 days prior. Shortly thereafter, The Board of Directors appointed Steve Guillen as President and CEO, leveraging Mr. Guillen’s extensive experience and proven track record in the health care industry, especially in the areas of sales and marketing and mergers and acquisitions.
Under Mr. Guillen’s leadership MedX began to explore other markets for their light products and acquired the Canadian rights to the RJ Laser line of products, which offered advances and features beyond the existing MedX product line. New markets were added including veterinary, auricular acupuncture, and dermatology. In early 2008, MedX Health also began to establish an international network of distributors and obtained the CE Mark for all of its products, opening the door to sales in the European Union.
In 2011, MedX Health announced the acquisition of the worldwide assets (Trademarks, IP, existing contracts, etc.) of an innovative skin imaging system called MoleMate™. MoleMate and its related technologies are FDA approved and CE Marked, and are currently being sold in Australia, New Zealand, Poland, the United Kingdom, and the US. MedX Health has licensed the use of a version of this technology for skin assessment to Proctor and Gamble for use in pharmacy and cosmetic point-of-sale counters to demonstrate to consumers the condition of their skin before and after the use of P&G skin products. In June of 2011, MedX began the US launch of MoleMate with an initial national team of 40 sales representatives calling on physicians. MoleMate and its related technologies are used by physicians to help gather extra information about their patient’s suspicious moles and lesions, by imaging pigment, collagen, and blood directly under the mole or lesions. For the first time, physicians will get clear, color images of these components via this ‘optical biopsy’, helping physicians and patients to come to a more informed decision about diagnosis and removal.
MedX Health Corp. – Management Team
Steve Guillen, B.Sc., M.B.A. – Chief Executive Officer, President and Director – Mr. Guillen has spent over 35 years in the health care industry in both public and private medical technology companies, and has extensive experience in the areas of sales & marketing and mergers & acquisitions. Prior to joining MedX, Mr. Guillen was Chief Executive Officer of OXIS International, Inc, a publicly traded medical technology company with FDA approved and developmental stage products in the medical device, pharmaceutical and OTC markets. Prior to that, Mr. Guillen was, for eight years, Vice President of Sales & Marketing for Amarin Pharmaceuticals, and Athena Diagnostics. Mr. Guillen began his career in medical technology companies at Merck & Co., where he spent 17 years, and was Head of Management Training, before he was recruited to establish his first commercial organization at Athena Neurosciences as Director of Sales.
Louie Canitano B,Sc. (N.H.) – Executive Vice President of Operations – Mr. Canitano has over 15 years of operational Healthcare experience. Mr. Canitano has covered all sectors including Sales and Marketing, Regulatory, IP and, Design and Development. Mr. Canitano was also awarded Patent as the Co-Inventor: WO/2006/050608 Method, Apparatus And Protocols For Performing Low Level Laser Therapy. As Founder of several companies such as RJ Laser Canada and Laserceuticals, Mr. Canitano was awarded distribution rights to the RJ Laser product line for Canada and the USA. Mr. Canitano obtained Health Canada and FDA approvals for several models and secured Eastern Currents as a major distributor. RJ Laser Canada and Laserceuticals were sold to MedX Health. Mr. Canitano began his career with managing several successful “G” Code and Schedule 5 OHIP physiotherapy clinics, introducing and utilizing laser therapy as a palliative modality. Of academic note, Mr. Canitano was a participant at the 5th Congress of the World Association for Laser Therapy (WALT) representing a sub-committee for industry.
Tim Maloney, B.A. – Worldwide Executive Vice President, Siascopy - Before joining MedX Health Corporation in 2011, Mr. Maloney was responsible for the worldwide growth and development of Siascopy technologies at Biocompatibles. Mr. Maloney joined Biocompatibles in January of 1998 working in Cardiology, Interventional Radiology, Interventional Oncology, Oncology, and Business Development. Prior to Biocompatibles, Mr. Maloney worked with C.R. Bard in Export, Cardiovascular, and Cardiology. Mr. Maloney has a double B.A. in History and in Philosophy from Holy Cross in the United States.
Symon Cotton, Ph.D. – Worldwide Director, Siascopy Technology – Created an international company specializing in the analysis of human skin and skin cancers. Dr. Cotton has developed products and technologies in regular use among physicians and by market leaders in the cosmetics industry including Proctor and Gamble, Boots and L’Oreal. Dr. Symon Cotton, trained originally in Physics before undertaking a Masters degree in Computer Science at Birmingham University, in the United Kingdom. After working as a software engineer for two years, he returned to the University to undertake a PhD in medical imaging where the combination of physics and robust software engineering led to the development of a novel optical system for investigating skin cancers. Following his PhD, Dr. Cotton founded Astron Clinica to commercially exploit the intellectual property generated during the PhD, playing a key role operating at the Board level, raising finance, managing intellectual property and driving product development. He has since become an expert in the analysis of human skin; developing SIAscopy in the assessment of a range of skin cancers and into the aesthetic and cosmetic analysis of skin. Dr. Cotton has over 50 publications to his name and 8 patents.
Larry Petersen, B.A. – Director of International Business Development – Mr. Petersen has more than 25 years of experience in the medical device business in the U.S. As Director of Sales and Marketing at Medtronic, he launched a new division responsible for cardiac pacemakers, stress testing equipment and Holter monitoring devices, where he exceeded the revenue projections for this division. Mr. Petersen also has experience working with the U.S. FDA to obtain new medical product approvals, as well as the FCC regulations for mobile devices.
Board Of Directors
Steven Guillen, B.Sc., M.B.A. – Chief Executive Officer, President and Director – Mr. Guillen has spent over 35 years in the health care industry in both public and private medical technology companies, and has extensive experience in the areas of sales & marketing and mergers & acquisitions. Prior to joining MedX, Mr. Guillen was Chief Executive Officer of OXIS International, Inc, a publicly traded medical technology company with FDA approved and developmental stage products in the medical device, pharmaceutical and OTC markets. Prior to that, Mr. Guillen was, for eight years, Vice President of Sales & Marketing for Amarin Pharmaceuticals, and Athena Diagnostics. Mr. Guillen began his career in medical technology companies at Merck & Co., where he spent 17 years, and was Head of Management Training, before he was recruited to establish his first commercial organization at Athena Neurosciences as Director of Sales.
David J. Hennigar, B.Com., M.B.A — Director – Mr. Hennigar is also Chairman of the board of directors of the following companies: Annapolis Basin Group Incorporated, Assisted Living Concepts Inc. (New York listed), Highliner Foods Inc., Aquarius Coatings Inc. ACQ, and VRI Technologies Inc. In addition, Mr. Hennigar is currently a director of the following companies: Landmark Global Financial Corporation, Sentex Systems Inc., Solution Inc., NHI, Scotia Investment Limited and Lead director of Crombie REIT.
Kenneth McKay, B.A., LL.B. — Director – Mr. McKay is a Senior Partner in the intellectual property law firm Sim, Lowman, Ashton & McKay. Mr. McKay is an active litigator in the intellectual property bar in Canada and is the co-author of several books and papers relating to intellectual property and the marketing and licensing of technology.
N.Gary Van Nest, B.Com., – Chairman and Director – Mr. Van Nest is President of Sinalta Investments Ltd., Chairman of Woodland Biofuels Inc. and holds several other directorships. Mr. Van Nest has over 35 years of extensive experience in the brokerage, merchant banking, and investment management businesses.
I gotta bookmark this internet site it seems very useful handy
Acupuncture is really a practice which is 2500 years old and improves the health of an individual. This Chinese remedy involves the use of needles on the body. The principle behind the therapy is that the body contains various channels or meridians by way of which energy flows continuously. Any blockage in these meridians can lead to pain or disorder within the corresponding part of the body. These meridians are also referred to as ‘Qi’. Wherever you will find perceived blockages inside the body, the needles are pricked on those particular points based on the issue. The needles would facilitate much better energy flow within the body and relieve pain.